[Clinical usefulness of positron emission tomography in prostate cancer].
In prostate cancer, use of FDG, the radiopharmaceutical currently most widely used in oncology, is limited to the most aggressive cancers and, in the absence of another tracer, to attempting to localise occult recurrences detected biochemically (elevated PSA serum levels). Four other PET tracers are currently suggested in various situations of prostate cancer development: for guiding biopsies, for diagnosis and staging of the primary cancer and of local or metastatic recurrences, especially in bone, and for localizing occult biochemical recurrence. This article is illustrated by cases summarising our experience with fluoromethylcholine-(18F) and PET/CT. They cover a wide spectrum of clinical settings: localisation of intraprostatic neoplastic lesions, initial staging, monitoring treatment by ultrasound, detection of occult recurrences and characterisation of images on conventional imaging modalities, which are questionable or difficult to interpret.
Talbot
Jean-Noël
JN
Service de médecine nucléaire, Hôpital Tenon, Université Pierre et Marie Curie, Paris. jean-noel.talbot@tnn.aphp.fr
Gutman
Fabrice
F
Huchet
Virginie
V
Kerrou
Khaldoun
K
Balogova
Sona
S
Kerrouche
Nacer
N
Montravers
Françoise
F
Grahek
Dany
D
Cussenot
Olivier
O
Gattegno
Bernard
B
Thibault
Philippe
P
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002794:Choline / Q000031:analogs & derivatives; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; C516370:fluoromethylcholine; D019788:Fluorodeoxyglucose F18; D002794:Choline